Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
4.92
-0.07 (-1.38%)
Jun 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.81 - 5.00
52 week 3.61 - 5.80
Open 5.00
Vol / Avg. 52,790.00/23,053.00
Mkt cap 39.55M
P/E 47.58
Div/yield     -
EPS 0.10
Shares 8.04M
Beta 0.04
Inst. own 19%
Aug 7, 2013
Q2 2013 CHEMBIO DIAGNOSTICS INC Earnings Release Add to calendar
Jun 7, 2013
CHEMBIO DIAGNOSTICS INC at Sidoti & Company Semi Microcap Conference
May 9, 2013
Q1 2013 CHEMBIO DIAGNOSTICS INC Earnings Conference Call
May 6, 2013
Q1 2013 CHEMBIO DIAGNOSTICS INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 6.25% 3.68%
Operating margin 8.96% 5.67%
EBITD margin - 7.71%
Return on average assets 11.78% 5.74%
Return on average equity 14.52% 7.14%
Employees 174 -
Carbon Disclosure Rating - -

Address

3661 Horseblock Road
MEDFORD, NY 11763
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Chembio Diagnostics, Inc. develops, manufactures and markets rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company�s main products are four rapid tests for the detection of human immunodeficiency virus (HIV) antibodies. Three of these products employ lateral flow technology, can be used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. The tests employing the cassette and barrel formats were approved by the United States Food and Drug Administration (FDA) and are distributed by Inverness Medical Innovations, Inc. (Inverness) in the United States. Its fourth rapid HIV test, which is developed on its Dual Path Platform (DPP) technology, detects antibodies to HIV in oral fluid samples, as well as all blood matrices.

Officers and directors

Lawrence A. Siebert Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Javan Esfandiari Executive Vice President - Research and Development
Age: 45
Bio & Compensation  - Reuters
Richard Bruce Vice President - Operations
Age: 58
Bio & Compensation  - Reuters
Michael Steele Vice President - Sales, Marketing & Business Development
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 49
Bio & Compensation  - Reuters
Katherine L. Davis Independent Director
Age: 55
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters